ACHV News and Press, Achieve Life Sciences Inc. From 01/09/23

SEATTLE, Wash and VANCOUVER, British Columbia, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, tod...

Achieve Life Sciences ( NASDAQ: ACHV ) said the U.S. Patent and Trademark Office (USPTO) issued Patent No. 11,459,328 covering the mesylate salt formulation of cytisinicline and the process for its development. The company noted that it is currently conducting a phase 3 trial, dub...

SEATTLE, Wash and VANCOUVER, British Columbia, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today an...

Achieve Life Sciences ( NASDAQ: ACHV ) on Tuesday announced an ~$18.9M private placement of its securities. The private placement will be for up to ~4.1M units at $4.625/unit, with each unit consisting of two shares and one warrant to buy a share. The private placement...

SEATTLE, Wash and VANCOUVER, British Columbia, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine depende...

Achieve Life Sciences, Inc. (ACHV) Q3 2022 Earnings Conference Call November 14, 2022 04:30 PM ET Company Participants Nicole Jones - Investor Relations-CG Capital John Bencich - Chief Executive Officer Jerry Wan - Principal Accounting Officer Cindy Jacobs - ...

Achieve Life Sciences press release ( NASDAQ: ACHV ): Q3 GAAP EPS of -$1.35 misses by $0.23 . As of September 30, 2022, the company’s cash, cash equivalents, and restricted cash were $18.2 million. Total operating expenses for the three months ended Septembe...

SEATTLE and VANCOUVER, British Columbia, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today...

SEATTLE, Wash and VANCOUVER, British Columbia, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for nicotine dependence, today announced that ...

SEATTLE, Wash and VANCOUVER, British Columbia, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine depende...